But winning EU approval for the novel anaemia pill was not straightforward, the Japanese firm says.
A low-key cancer discovery alliance sees Roche abandoning its earlier opposition to cell therapies.
A project from SK Bioscience and Glaxo started phase 3 this week, but it is far from the only late-stage candidate.
The Danish group reports promising mid-stage data with its respiratory syncytial virus vaccine, but competition is fierce.
Drugs prompting the most divergent opinions on outlook include Pfizer and Vir’s Covid-19 offerings and Biogen’s Aduhelm.